{
  "docId": "019de076-8eed-77e6-97e7-f406514b962a",
  "docSlug": "e8bbfe027845ab55cba77860ad12e49b",
  "documentTitle": "Absci | Investor Conference Presentation Deck | 22 slides",
  "authorId": "absci",
  "authorName": "Absci",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 22,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The table uses checkmarks and crosses to indicate the presence or absence of specific therapeutic attributes across four different drug programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8eed-77e6-97e7-f406514b962a/18",
  "deckHref": "/decks/019de076-8eed-77e6-97e7-f406514b962a",
  "deckJsonHref": "/decks/019de076-8eed-77e6-97e7-f406514b962a.json",
  "deckAnchorHref": "/decks/019de076-8eed-77e6-97e7-f406514b962a#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.08,
        "y": 0.73
      },
      "kind": "disclaimer",
      "text": "* Projected ABS-101 attributes derived from in silico and in vitro metrics and modeled exposure with ½-life extension ** Low score by 2 in silico immunogenicity metrics and low results in ex vivo testing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "442a96a0-65ee-4a53-94fa-443e9493e54c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.08,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "1 Based on Phase 2 data 2 Expected commercial form factor 3 Once monthly dosing regimen 4 45% BA at 100mg/mL based on Ph2 Data 5 Danase et al 2021 (Pfizer Phase 2 data) reports 41 participants out of 50 participants (82%) developing ADA, and 5 (10%) of these developed neutralizing ADA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c26e41b-296a-4bce-a99b-66d49c0ff97d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.84,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "table",
      "text": "Comparison table of attributes: Low Immunogenicity, High Bioavailability, Sub-Q autoinjector, Q8W to once quarterly dosing across ABS-101, Merck, Roche, and Sanofi.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92107b93-8196-481e-a138-2310bc5976a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "AI Platform Designed ABS-101 Aims for Optimal Therapeutic Profile",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "854134e3-4487-4de4-8414-1572d8689aeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "ABS-101 TL1A DATA HIGHLIGHTS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b24e9389-eb75-42cc-a3ed-afcf79c7ad68",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "f41652a3-0ce4-4c59-9eb5-afc4f0769e6c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation showcases Absci's solution and its potential benefits.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}